Qlife Holding AB (QLIFE) AI Stock Analysis

• Market Cap: kr26.09M
• Dividend Yield: N/A
• Average Volume (3M): 97.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.63
• Revenue Growth: 376.81%
• EPS Growth: 97.95%
• Country: SE
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.73
• Shares Outstanding: 12,484,911
• 10 Day Avg. Volume: 81,486
• 30 Day Avg. Volume: 97,188
• PEG Ratio: -0.76
• Price to Book (P/B): -911.64
• Price to Sales (P/S): 26054.69
• P/FCF Ratio: -24.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: kr2.00 ▼(-33.55% Downside)

The overall stock score is primarily impacted by significant financial challenges, including declining revenue, persistent losses, and negative equity. While technical analysis shows some positive momentum, the negative valuation metrics further weigh down the score. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Innovative Product Offering

Qlife's focus on advanced diagnostic tools and personalized medicine positions it well in the growing healthcare sector, offering potential for long-term growth through innovation.

Revenue Growth Potential

The significant revenue growth indicates strong demand for Qlife's products and services, suggesting potential for continued expansion and market penetration.

Strategic Partnerships

Partnerships with healthcare and pharmaceutical companies can enhance Qlife's market reach and product development, providing a durable competitive advantage.

Negative Factors

Financial Instability

Negative equity indicates financial instability, posing risks to long-term viability and limiting the company's ability to invest in growth opportunities.

Cash Flow Challenges

Persistent negative cash flow suggests reliance on external financing, which can strain financial resources and limit operational flexibility.

Operational Inefficiencies

Negative margins indicate high operational costs relative to revenue, reflecting inefficiencies that could hinder profitability and growth.

Qlife Holding AB Business Overview & Revenue Model

Company Description

Qlife Holding AB (QLIFE) is a biotechnology company based in Sweden, specializing in the development of advanced diagnostic tools aimed at improving patient care and health outcomes. The company focuses on innovative solutions in the healthcare sector, particularly in the areas of personalized medicine and point-of-care diagnostics. Qlife's core products include its proprietary diagnostic platforms, which utilize advanced technology to deliver rapid and accurate health assessments.

How the Company Makes Money

QLIFE generates revenue primarily through the sale of its diagnostic products and services. The company offers its proprietary testing platforms to hospitals, clinics, and laboratories, which pay for the devices and associated consumables. Additionally, Qlife may engage in partnerships with healthcare organizations and pharmaceutical companies to develop customized diagnostic solutions, leading to revenue-sharing agreements. The company also explores opportunities in research collaborations and grants, which can provide additional funding and support for its product development initiatives. Continued growth may be driven by expanding its market presence and enhancing product offerings to meet the evolving needs of the healthcare industry.

Qlife Holding AB Financial Statement Overview

Summary

Qlife Holding AB faces considerable financial challenges with declining revenue, persistent losses, negative equity, and weak cash flows. The firm's high reliance on external financing and inability to generate positive cash flow or profit raises concerns about its long-term viability and financial health.

Income Statement

Qlife Holding AB has experienced significant challenges in its income statement with declining total revenue from 2021 onwards and continuous negative net income. The gross profit margin is positive but the net profit margin is negative due to high operational expenses. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet indicates financial instability with negative stockholders' equity in 2023 and 2024, suggesting more liabilities than assets. The debt-to-equity ratio is unmanageable due to negative equity, and the equity ratio is also negative, highlighting high financial leverage risk and potential insolvency.

Cash Flow

Cash flow statements show a consistent negative free cash flow and operating cash flow, indicating cash outflows surpassing inflows. Despite high financing cash flow, the operating cash flow to net income ratio and free cash flow to net income ratio remain negative, suggesting that the company is heavily reliant on external financing to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	329.00K	50.00K	244.00K	17.99M	39.61M	20.75M
Gross Profit	-7.11M	-158.00K	-6.31M	-10.75M	44.54M	35.68M
EBITDA	-24.29M	-12.46M	-150.50M	-78.05M	-35.13M	-19.49M
Net Income	-25.16M	-55.98M	-159.96M	-93.14M	-38.80M	-20.20M
Balance Sheet
Total Assets	12.70M	11.64M	39.05M	192.65M	193.44M	127.19M
Cash, Cash Equivalents and Short-Term Investments	2.81M	2.71M	1.66M	14.55M	73.46M	20.82M
Total Debt	8.55M	8.70M	20.25M	52.44M	4.72M	3.96M
Total Liabilities	17.96M	13.07M	62.17M	101.50M	30.26M	37.64M
Stockholders Equity	-5.27M	-1.43M	-23.12M	91.15M	132.50M	89.55M
Cash Flow
Free Cash Flow	-24.30M	-54.17M	-62.64M	-90.67M	-52.82M	-43.66M
Operating Cash Flow	-15.60M	-37.37M	-41.80M	-47.73M	-26.05M	-16.83M
Investing Cash Flow	-8.70M	-16.80M	-20.84M	-42.94M	-26.77M	-26.83M
Financing Cash Flow	23.98M	55.23M	49.00M	32.73M	106.02M	58.91M

Qlife Holding AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.01
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:QLIFE, the sentiment is Positive. The current price of 3.01 is above the 20-day moving average (MA) of 1.96, above the 50-day MA of 1.99, and above the 200-day MA of 2.83, indicating a neutral trend. The MACD of 0.17 indicates Negative momentum. The RSI at 56.26 is Neutral, neither overbought nor oversold. The STOCH value of 23.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:QLIFE.

Qlife Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
QLIFE	46 Neutral	kr26.09M	-0.47	―	―	376.81%	97.95%
SPEC	39 Underperform	kr67.42M	-0.77	-50.21%	―	―	-108.64%
LXB	38 Underperform	kr63.77M	-2.70	-60.20%	―	163.12%	30.50%
HEART	34 Underperform	kr135.96M	-0.84	―	―	―	―